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Abstract
The small molecule 4EGI-1 was identified as an inhibitor of cap-dependent translation initiation owing to its disruption
of the eIF4E/eIF4G association through binding to eIF4E. 4EGI-1 exhibits growth-inhibitory and apoptosis-inducing
activity in cancer cells; thus, we were interested in its therapeutic efficacy in human lung cancer cells. 4EGI-1, as a
single agent, inhibited the growth and induced apoptosis of human lung cancer cells. When combined with the death
ligand tumor necrosis factor–related apoptosis-inducing ligand (TRAIL), enhanced apoptosis-induced activity was ob-
served. As expected, 4EGI-1 inhibited eIF4E/eIF4G interaction and reduced the levels of cyclinD1 and hypoxia-inducing
factor-1α (HIF-1α), both of which are regulated by a cap-dependent translation mechanism. Moreover, 4EGI-1 in-
duced CCAAT/enhancer–binding protein homologous protein–dependent DR5 expression and ubiquitin/proteasome–
mediated degradation of cellular FLICE-inhibitory protein (c-FLIP). Small interfering RNA–mediated blockade of
DR5 induction or enforced expression of c-FLIP abrogated 4EGI-1’s ability to enhance TRAIL-induced apoptosis, in-
dicating that both DR5 induction and c-FLIP down-regulation contribute to enhancement of TRAIL-induced apoptosis
by 4EGI-1. However, inhibition of eIF4E/eIF4G interaction by knockdown of eIF4E effectively reduced the levels of
cyclin D1 and HIF-1α but failed to induce DR5 expression, downregulate c-FLIP levels, or augment TRAIL-induced
apoptosis. These results collectively suggest that 4EGI-1 augments TRAIL-induced apoptosis through induction of
DR5 and down-regulation of c-FLIP, independent of inhibition of cap-dependent protein translation.
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Introduction
Protein translational control is an important strategy by which eukaryotic
cells regulate gene expression. A prime target of translational control is
eukaryotic translation initiation factor 4E (eIF4E), which recognizes and
binds to the 7-methylguanosine cap structure present at the 5′ untrans-
lated regions of cellular messenger RNA (mRNA) and delivers these
mRNA to the eIF4F translation initiation complex, which is composed
of the cap-binding protein eIF4E, the RNA helicase eIF4A, and the scaf-
folding protein eIF4G [1,2]. Assembly of the eIF4F complex is depen-
dent on eIF4E availability. Given that eIF4E is the least abundant
among the initiator factors involved in the eIF4F complex, eIF4E is
the rate-limiting factor for cap-dependent translation initiation [2]. Con-
sequently, changes in eIF4E levels profoundly affect translation rates of
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certain proteins, particularly those related to cell growth and survival in-
volved in oncogenesis (e.g., c-Myc, vascular endothelial growth factor,
ODC, cyclinD1, hypoxia-inducing factor-1 [HIF-1], andMcl-1), which,
under normal cellular conditions, are translationally repressed [3,4]. Un-
der normal cellular conditions, eIF4E is bound by the inhibitory 4E-BPs,
which sequester eIF4E from interaction with eIF4G, preventing the
formation of the eIF4F translation initiation complex. The activities of
4E-BPs are regulated by phosphorylation through the mammalian target
of rapamycin (mTOR) pathway. Hypophosphorylated 4E-BPs sequester
eIF4E, inhibiting translation, whereas hyperphosphorylated 4E-BPs do
not bind eIF4E and the eIF4E is free to participate in translation initia-
tion. The 4E-BPs compete with eIF4G for binding to eIF4E because
they share the same binding motif on eIF4E [5–7].
Abnormal regulation of cellular eIF4F caused by elevated levels of
initiation factors or dysregulation of 4E-BP phosphorylation plays an
important role in oncogenesis. eIF4E expression is frequently elevated
in many types of cancers and is associated with malignant progression
[5,8]. Enforced overexpression of eIF4E in experimental systems in-
duces cell transformation and tumorigenesis both in cell cultures and
in animal models [4,9–12]. Similar results were also observed when
eIF4G was overexpressed [13]. Conversely, ectopic expression of 4E-
BPs can partially revert eIF4E-transformed cells to a nonmalignant
phenotype [14] and induce apoptosis in cells transformed by other
oncogenes such as Ras [9,15]. Thus, the eIF4F complex and eIF4E
are considered to be promising cancer therapeutic targets. Accordingly,
eIF4E-specific antisense oligonucleotides have been shown to effectively
repress the expression of eIF4E-regulated proteins (e.g., vascular endothe-
lial growth factor, cyclin D1, survivin, c-Myc, Bcl-2), induce apoptosis,
inhibit tumor growth in vivo with minimal toxicity, and are now being
tested in phase 1 clinical trials [16]. Several rapamycin analogs, which de-
crease eIF4F levels by inhibiting mTOR-dependent 4E-BP phosphoryla-
tion, have antitumor activity and have been approved for cancer treatment
or are being evaluated as cancer drugs in clinical trials [17–19].
The death ligand tumor necrosis factor–related apoptosis-inducing
ligand (TRAIL), which induces apoptosis on binding to its receptors
death receptors 4 and 5 (DR4 and DR5), has recently received much
attention because it preferentially induces apoptosis in transformed or
malignant cells but not in most normal cells [20]. Currently, recombi-
nant human TRAIL is being tested as an anticancer agent in phase 1
clinical trials [21]. In addition, agonistic antibodies against DR4 and
DR5, which directly activate the extrinsic apoptotic pathway, have
been developed and tested in phase 1 or 2 trials and found to be well
tolerated [22,23]. Thus, death receptor–mediated apoptosis, particu-
larly TRAIL death receptor–mediated apoptosis, has been subject to
intense research as a cancer therapeutic target [23,24]. However, an
important issue in this regard is the intrinsic resistance of certain cancer
cells to TRAIL/death receptor–induced apoptosis [25]. Fortunately,
certain cancer therapeutic agents can sensitize various types of cancer
cells to TRAIL-induced apoptosis or overcome the intrinsic apoptotic
resistance to TRAIL [26]. Accordingly, these agents are potentially
useful in combination with TRAIL or TRAIL receptor agonistic anti-
bodies to enhance TRAIL- or TRAIL receptor–based cancer therapy.
TRAIL/death receptor–mediated apoptosis is primarily inhibited by
cellular FLICE-inhibitory protein (c-FLIP), which inhibits caspase-8 ac-
tivation by preventing recruitment of caspase-8 to the death-inducing
signaling complex called DISC [27,28]. c-FLIP has multiple splice
variants, however, only two of them (i.e., FLIPL and FLIPS) have
been well characterized at the protein levels [29,30]. The levels of
c-FLIP, including both FLIPL and FLIPS, are subject to regulation by
ubiquitin/proteasome–mediated degradation [31–33]. It has been well
documented that elevated c-FLIP expression protects cells from death
receptor–mediated apoptosis, whereas down-regulation of c-FLIP by
chemicals or small interfering RNA (siRNA) sensitizes cells to death
receptor–mediated apoptosis [29]. Moreover, overexpression of c-FLIP
also protects cells from apoptosis induced by cancer therapeutic agents
such as etoposide and cisplatin [34–38].
The small molecule, 4EGI-1, has been identified through high-
throughput screens of compound libraries to bind eIF4E and disrupt
eIF4E/eIF4G association. This compound selectively inhibits cap-
dependent translation and exhibits activity against multiple cancer cell
lines including induction of apoptosis [39]. We are interested in its
therapeutic activity in lung cancer. Moreover, we are particularly inter-
ested in identifying small molecules that can sensitize cancer cells to
TRAIL-induced apoptosis. Interestingly, we found that 4EGI-1 alone
not only induced apoptosis of human lung cancer but also cooperated
with TRAIL in augmenting apoptosis. Thus, we focused our study on
revealing the mechanisms by which 4EGI-1 enhances TRAIL-induced
apoptosis and the role of cap-dependent translation in this process.
Materials and Methods
Reagents
4EGI-1 was purchased from EMD Chemicals, Inc, or Calbiochem
(Gibbstown, NJ). It was dissolved in DMSO at the concentration of
100 mM, and aliquots were stored at −80°C. Stock solutions were
diluted to the appropriate concentrations with growth medium im-
mediately before use. The soluble recombinant human TRAIL was
purchased from PeproTech, Inc (Rocky Hill, NJ). The proteasome
inhibitor MG132 and the protein synthesis inhibitor cycloheximide
(CHX) were purchased from Sigma Chemical Co (St Louis, MO).
Rabbit polyclonal anti-DR5 antibody was purchased from ProSci, Inc
(Poway, CA).Mouse monoclonal anti-DR4 antibody (B-N28) was pur-
chased from Diaclone (Stamford, CT). Mouse monoclonal anti-FLIP
antibody (NF6) was purchased Alexis Biochemicals (San Diego, CA).
Rabbit polyclonal anti–caspase-8, anti-poly(ADP-ribose) polymerase
(PARP), and anti–phospho-elF2α (Ser51) antibodies were purchased
from Cell Signaling Technology, Inc (Beverly, MA). Mouse monoclonal
c-Myc (9E10), anti–CCAAT/enhancer–binding protein homologous
protein (CHOP) (B-3) antibodies, and rabbit polyclonal ATF4 (CREB-2;
C-20) were purchased from Santa Cruz Biotechnology, Inc (Santa Cruz,
CA). Mouse monoclonal cyclin D1 antibody (clone DCS-6) was pur-
chased from Dako (Carpinteria, CA). Mouse monoclonal anti–β-actin
and rabbit polyclonal anti-GAPDH antibodies were purchased from
Sigma Chemical Co and Trevigen, Inc (Gaithersburg, MD), respectively.
Cell Lines and Cell Culture
Human non–small cell lung cancer cell lines used in this study were
purchased from the American Type Culture Collection (Manassas, VA).
The H157-Lac Z-5, H157-FLIPL-21 and H157-FLIPS-1 stable trans-
fectants that express control Lac Z, ectopic FLIPL, and ectopic FLIPS,
respectively, were described previously [40]. These cell lines were cul-
tured in RPMI 1640 containing 5% fetal bovine serum at 37°C in a
humidified atmosphere of 5% CO2 and 95% air.
Cell Survival Assay
Cells were seeded in 96-well cell culture plates and treated the next
day with the agents indicated. The viable cell number was determined
using the sulforhodamine B (SRB) assay, as previously described [41].
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Detection of Apoptosis
Apoptosis was evaluated by Annexin V staining using Annexin V–PE
apoptosis detection kit purchased from BD Biosciences (San Jose, CA)
following the manufacturer’s instructions. We also detected PARP
cleavage by Western blot analysis (as described below) as an additional
indicator of apoptosis.
Western Blot Analysis
Whole-cell protein lysates were prepared and analyzed by Western
blot analysis as described previously [42,43].
Detection of DR5 mRNA
DR5 mRNA levels were detected with reverse transcription–
polymerase chain reaction (RT-PCR) as described previously [44].
7-Methyl GTP Pull-down for Analysis of eIF4F
Complex Formation
eIF4F complex in cell extracts was detected using affinity chroma-
tography 7-methyl GTP (m7GTP)–Sepharose as described previously
[45]. Briefly, the given cells were lysed in buffer containing 20 mM
Tris-HCl (pH 7.4), 150 mM NaCl, 1 mM EDTA, 1 mM EGTA,
1 mM β-glycerophosphate, 1 mM Na3VO4, 1% Triton X-100, 2.5 mM
sodium pyrophosphate, and protease inhibitor cocktail, on ice for 15 min-
utes. After centrifugation at 12,000g for 15 minutes at 4°C, the super-
natants were collected and incubated with m7GTP-Sepharose (GE
Healthcare Bio-Sciences, Corp/Amersham, Piscataway, NJ) at 4°C for
2 hours with constant shaking. Beads were washed three times with
lysis buffer and three times with 1 × PBS. The samples were then dena-
tured, and the supernatants were then loaded to SDS-PAGE for Western
blot analysis.
Immunoprecipitation for Detection of Ubiquitinated c-FLIP
H157-FLIPL-21 cells, which stably express FLIPL, were transfected
with HA-ubiquitin plasmid using the FuGENE 6 transfection reagent
(Roche Diagnostics Corp, Indianapolis, IN) following the manufac-
turer’s instructions. After 24 hours, the cells were treated with 4EGI-1
or MG132 plus 4EGI-1 for the given time and were then lysed for
immunoprecipitation of Flag-FLIPL using Flag M2 monoclonal anti-
body (Sigma) as previously described [46] followed by the detection
of ubiquitinated FLIPL with Western blot analysis using anti-HA anti-
body (Abgent, San Diego, CA).
SiRNA-Mediated Gene Silencing
The siRNA duplexes for nonsilencing control, DR5, and CHOP
were described previously [43,44]. eIF4E siRNA (5′-GGACGAUGG-
CUAAUUACAUdTdT-3′) was described previously [47]. Transfection
of these siRNA duplexes was conducted in six-well plates using the
HiPerFect transfection reagent (Qiagen, Valencia, CA) following the
manufacturer’s manual. The gene-silencing effect was evaluated by
Western blot analysis.
Transient Transfection and Luciferase Activity Assay
The reporter constructs harboring different DR5 5′-flanking regions,
transient transfection, and luciferase assay were all the same as described
previously [44,48].
Results
4EGI-1 Inhibits the Growth of Lung Cancer Cells and
Cooperates with TRAIL to Augment Apoptosis
We first determined the effects of 4EGI-1 as a single agent on the
growth of human lung cancer cells. As presented in Figure 1A, 4EGI-1
at a concentration range of 20 to 50 μM effectively inhibited the growth
of the panel of lung cancer cell lines, with halfmaximal inhibitory concen-
tration values, around 40 μM under the tested conditions. Moreover, it
clearly induced the cleavage of PARP, a hallmark of apoptosis, in the tested
lung cancer cell lines evidenced by the appearance of cleaved band and/or
reduction of intact PARP (Figure 1B), suggesting that 4EGI-1 also in-
duces apoptosis. When combined with TRAIL, enhanced effects on de-
creasing cell survival were observed in every tested cell line because the
combination of 4EGI-1withTRAILwasmuchmore effective than either
4EGI-1 or TRAIL alone in decreasing the survival of the lung cancer cells
(Figure 2A). ByWestern blot analysis, we detected more sever cleavage of
caspases including caspase-3, caspase-8, and caspase-9 and PARP in cells
treated with 4EGI-1 and TRAIL than those treated with 4EGI-1 or
TRAIL alone (Figure 2B), evidenced by either reduction of proforms
of the caspases or appearance of the cleaved bands. Also, direct detection
of apoptosis with Annexin V staining showed that the combination of
4EGI-1 and TRAIL was more potent than either single agent alone in
Figure 1. 4EGI-1 inhibits the growth of human lung cancer cells
(A) and induces PARP cleavage (B). (A) The indicated lung cancer cell
lines were seeded in 96-well cell culture plates and treated the next
day with the given concentrations of 4EGI-1. After 3 days, cell num-
bers were estimated using the SRB assay. Cell survival was ex-
pressed as the percent of control (DMSO-treated) cells. Data are
the means of four replicate determinations. Bars, ±SDs. (B) The in-
dicated cancer cell lines were treated with the given concentrations
of 4EGI-1 for 24 hours. The cells were then harvested for preparation
of whole-cell protein lysates and subsequent Western blot analysis
for detecting PARP cleavage. CF indicates cleaved fragment.
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inducing apoptosis (Figure 2C). Specifically, the 4EGI-1 and TRAIL com-
bination induced apoptosis in approximately 46%of cells, whereas 4EGI-1
and TRAIL alone induced apoptosis in approximately 20% and 8% of
cells, respectively (Figure 2C ). Collectively, these results indicate that
4EGI-1 cooperates with TRAIL to augment the induction of apoptosis.
4EGI-1 Modulates DR5 and c-FLIP Levels That Contribute
to Cooperative Induction of Apoptosis by the Combination
of 4EGI-1 and TRAIL
To determine the mechanism by which 4EGI-1 cooperates with
TRAIL to augment apoptosis, we analyzed the modulatory effects of
4EGI-1 on DR4, DR5, and c-FLIP, which are often involved in
drug-induced sensitization of TRAIL/death receptor–induced apopto-
sis [26]. As shown in Figure 3A, 4EGI-1 increased DR5 expression and
reduced c-FLIP (both FLIPL and FLIPS) levels in every tested cell line;
however, it decreased DR4 expression in these cell lines. Thus, we fo-
cused our further analyses on DR5 and c-FLIP. By time course analysis
of the effects of 4EGI-1 on DR5 and c-FLIP, we observed that DR5
induction occurred at 12 hours and c-FLIP reduction happened at
3 hours after 4EGI-1 treatment. Both DR5 induction and c-FLIP
reduction were sustained up to 24 hours (Figure 3B). It appears that
c-FLIP reduction precedes DR5 induction in 4EGI-1–treated cells.
Figure 2. 4EGI-1 enhances TRAIL-induced apoptosis as evaluated by cell survival (A), caspase activation (B), and Annexin V staining (C).
(A) The indicated cell lines were seeded in 96-well cell culture plates and treated the next day with the given concentrations of 4EGI-1 alone,
TRAIL alone, or their respective combinations. After 24 hours, cell numbers were estimated using the SRB assay. Data are the means of
four replicate determinations. Bars, ±SDs. (B) The indicated cell lines were treated with 20 ng/ml TRAIL alone, 50 μM 4EGI-1 alone, and
their combination. After 24 hours, the cells were harvested for preparation of whole-cell protein lysates and subsequent Western blot analy-
sis. CF indicates cleaved fragment. (C) A549 cells were treated with 40 ng/ml TRAIL alone, 40 μM 4EGI-1 alone, and their combination. After
24 hours, the cells were subjected to measurement of apoptosis using Annexin V staining. The percent positive cells in the upper right and
lower right quadrants were added to yield the total of apoptotic cells.
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We next asked whether c-FLIP reduction participated in cooperative
induction of apoptosis by 4EGI-1 and TRAIL combination. To this
end, we tested the apoptosis-inducing effects of 4EGI-1 and TRAIL
combination in cell lines that overexpress ectopic c-FLIP (both FLIPL
and FLIPS). We assumed that overexpression of ectopic c-FLIP prevents
endogenous c-FLIP reduction and thus confers cell resistance to 4EGI-1/
TRAIL–induced apoptosis if the c-FLIP is important for cooperative
induction of apoptosis by 4EGI-1 and TRAIL combination. Indeed,
both TRAIL alone and 4EGI-1 combined with TRAIL induced much
less apoptosis in the cell lines that expressed either ectopic FLIPL or
FLIPS than the control cell line that expressed the irrelevant protein
Lac Z (Figure 3C), indicating that expression of ectopic c-FLIP clearly
protects cells from 4EGI-1/TRAIL–induced apoptosis. Thus, we con-
clude that c-FLIP down-regulation contributes to cooperative induction
of apoptosis by the 4EGI-1 and TRAIL combination.
Furthermore, we determined whether DR5 induction is important
for enhancement of TRAIL-induced apoptosis by 4EGI-1 by knock-
ing down DR5 expression and then examining its impact on 4EGI-1
and TRAIL-induced apoptosis. As shown in Figure 3D, transfection
of DR5 siRNA decreased not only the basal levels of DR5 but also
4EGI-1–induced DR5 up-regulation (left panel ), indicating success-
ful knockdown of DR5 expression. Accordingly, the 4EGI-1 and
TRAIL combination potently induced PARP cleavage (left panel ) and
increased the percentage of apoptotic cells (right panel ) in control
siRNA–transfected cells but only minimally in DR5 siRNA-transfected
cells. Moreover, the effects of 4EGI-1 or TRAIL alone on PARP cleavage
Figure 3. 4EGI-1 modulates the levels of DR5 and c-FLIP (A and B), which contribute to enhancement of TRAIL-induced apoptosis (C and
D). (A and B) The given cell lines were treatedwith different concentrations of 4EGI-1 as indicated for 24 hours (A) or 50 μM4EGI-1 for various
times from 3 to 24 hours as indicated and then subjected to preparation of whole-cell protein lysates and subsequent Western blot analy-
sis for the given proteins. (C) The H157 cell lines Lac Z-5, FLIPL-21 and FLIPS-1, which express different ectopic FLIPs, as detected by
Western blot analysis (left panel), were treated with DMSO, 50 μM4EGI-1 alone, 20 ng/ml TRAIL alone or 4EGI-1 plus TRAIL. After 24 hours,
the cells were harvested and subjected to detection of apoptosis by Annexin V staining (right panel). Columns indicate means of duplicate
experiments; bars, ±SE. (D) A549 cells were cultured in a six-well plate and, the next day, transfectedwith 60 nMcontrol (Ctrl) or DR5 siRNA.
Forty-eight hours after transfection, the cells were treated with 40 μM4EGI-1 alone, 20 ng/ml TRAIL alone, or 4EGI-1 plus TRAIL for 24 hours
and then harvested for detection of apoptosis by Annexin V staining. Columns indicate means of duplicate experiments; bars, ±SE.
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and induction of apoptosis were attenuated in DR5 siRNA-transfected
cells compared with their effects in control siRNA–tranfected cells
(Figure 3D). Thus, these results clearly indicate that DR5 induction
also contributes to cooperative induction of apoptosis by the 4EGI-1
and TRAIL combination. It is likely that DR5 induction is also impor-
tant for 4EGI-1–induced apoptosis.
4EGI-1 Enhances TRAIL-Induced Apoptosis Independent of
Its Inhibitory Effect on Cap-Dependent Protein Translation
Given that 4EGI-1 was developed as an eIF4E/eIF4G interaction
inhibitor [39], we asked whether the effects of 4EGI-1 on DR5 induc-
tion, c-FLIP reduction, and enhancement of TRAIL-induced apoptosis
are secondary to its inhibition of cap-dependent protein translation.
Thus, we first analyzed whether 4EGI-1 inhibits eIF4E and eIF4G
interaction or eIF4F complex formation in our cell systems. In an
m7GTP pull-down assay, we detected much lower amounts of eIF4G
in 4EGI-1–treated cells than in DMSO-treated cells (Figure 4A),
indicating that 4EGI-1 indeed disrupts the formation of eIF4F com-
plex in our cell systems as reported [39]. Moreover, we examined the
effects of 4EGI-1 on the expression of cyclin D1 and HIF-1α, which
are known to be regulated through cap-dependent translation ini-
tiation mechanisms. As presented in Figure 4B, 4EGI-1 decreased
the levels of both cyclin D1 and HIF-1α in concentration- and time-
dependent manners, suggesting that 4EGI-1 inhibits cap-dependent
protein translation. We noted that HIF-1α expression was not detected
in A549 and H460 cells; this is likely due to the normoxia condition in
our experiment.
After these studies, we determined whether knockdown of eIF4E
with eIF4E siRNA can generate similar effects as 4EGI-1 does in induc-
ing DR5 expression, reducing c-FLIP levels and enhancing TRAIL-
induced apoptosis. Knockdown of eIF4E effectively decreased cyclin
D1 levels but not c-FLIP levels. Interestingly, eIF4E knockdown ac-
tually decreased DR5 levels (Figure 4C). When treated with TRAIL,
we detected comparable levels of the cleavage of caspase-8 and PARP
(Figure 4D) and similar percentages of apoptotic cells (Figure 4E ).
These results indicate that inhibition of eIF4E with eIF4E siRNA does
not increase DR5 expression, reduce c-FLIP levels, or sensitize cells to
TRAIL-induced apoptosis.
Furthermore, we checked the effects of rapamycin, an mTOR in-
hibitor that is known to inhibit cap-dependent protein translation
[49], on modulation of DR5, c-FLIP and TRAIL-induced apoptosis.
Treatment of cells with rapamycin inhibited the phosphorylation of
S6, a known readout of mTOR signaling activity, and decreased the
levels of cyclin D1 and HIF-1α but did not increase DR5 or reduce
c-FLIP levels (FigureW1A). Similarly, treatment of cells with rapamycin
combined with TRAIL did not show any enhanced effects on decreasing
cell survival (Figure W1B). Together, these results further our notion
that 4EGI-1 cooperates with TRAIL to augment apoptosis independent
of inhibition of cap-dependent protein translation.
4EGI-1 Induces DR5 Expression through a
CHOP-Dependent Mechanism
To understand how 4EGI-1 upregulates DR5 expression, we then
checked whether 4EGI-1 increases DR5 expression at the transcriptional
level. By RT-PCR, we detected concentration-dependent increases of
DR5 mRNA in cells exposed to 4EGI-1 (Figure 5A). Moreover, 4EGI-1
increased DR5 promoter activity (Figure 5B). These results indicate
that 4EGI-1 indeed increases DR5 expression at the transcriptional
level. Through deletion analysis of the DR5 promoter region, we noted
that the region between −373 and −240 is critical for 4EGI-1 to trans-
activate the DR5 promoter because the DR5 −240 promoter fragment
lost activity to respond to 4EGI-1, whereas the DR5 −373 fragment
maintained its response to 4EGI-1 treatment (Figure 5B). It has been
documented that the CHOP is a critical transcriptional factor that regu-
latesDR5 expression [44,50,51].We noted that the CHOP binding site
locates at the region between −373 and −240 of the DR5 promoter.
Thus, we questioned whether the CHOP binding site is responsible
for 4EGI-1–mediated transactivation of the DR5 promoter. To this
end, we compared the effects of 4EGI-1 on transcriptional activity of
the DR5 promoter reporter construct with and without wild-type
CHOP binding site. As expected, 4EGI-1 increased the luciferase ac-
tivity in cells transfected with pGL3-DR5(−552) carrying the wild-
type CHOP binding site but failed to do so in cells transfected with
pGL3-DR5(−552)CHOPm, in which the CHOP binding site was in-
activated (Figure 5C). Together, these results suggest that CHOPmight
be an important transcriptional factor responsible for 4EGI-1–induced
DR5 up-regulation.
Subsequently, we determined whether 4EGI-1 indeed alters CHOP
expression. As presented in Figure 5D, 4EGI-1 increased CHOP levels
in both A549 and H358 cells (top panel ); this effect occurred at 6 hours
after 4EGI-1 treatment, peaked at 12 hours and was sustained up to
24 hours (bottom panel ). In addition, we found that 4EGI-1 increased
the levels of ATF4 and p-eIF2α (Figure 5D), two proteins known to
be increased during endoplasmic reticulum (ER) stress. Thus, it seems
that 4EGI-1 induces CHOP expression with ER stress. To prove that
CHOP is critical forDR5 induction by 4EGI-1, we usedCHOPsiRNA
to knock down CHOP expression and then examined its impact on
4EGI-1–induced DR5 expression. As shown in Figure 5E , transfection
of CHOP siRNA effectively blocked not only CHOP up-regulation by
4EGI-1 but also 4EGI-1–induced DR5 up-regulation, indicating that
4EGI-1 induces DR5 expression through a CHOP-dependent mecha-
nism. Moreover, we detected increased cleavage of PARP in 4EGI-1–
treated cells transfected with control siRNA but not in 4EGI-1–treated
cells transfected with CHOP siRNA, suggesting that both CHOP and
DR5 up-regulation are also important for 4EGI-1–induced apoptosis.
4EGI-1 Downregulates c-FLIP Levels through Ubiquitin/
Proteasome–Mediated Degradation
We also determined the mechanism by which 4EGI-1 reduces
c-FLIP levels. Because c-FLIP proteins are known to be regulated
by ubiquitin/proteasome–mediated degradation [31–33], we asked
whether the observed down-regulation of c-FLIP by 4EGI-1 would be
mediated through this process. Thus, we first determined whether
4EGI-1 affects c-FLIP stability. To this end, we treated H157 cells with
either DMSO solvent control or 4EGI-1 for 5 hours and then washed
away the drug followed by refilling the cells with fresh medium con-
taining CHX. At the indicated times after addition of CHX, the cells
were harvested for Western blot analysis for analyzing c-FLIP degrada-
tion rate. As presented in Figure 6A, the half-lives for FLIPL and FLIPS
in control cells were approximately 60 and 30 minutes, respectively;
however, they were approximately 15 and 20 minutes, respectively, in
4EGI-1–treated cells. Thus, it is clear that 4EGI-1 facilitates c-FLIP
degradation. Moreover, we examined the effects of 4EGI-1 on c-FLIP
in the absence and presence of the proteasome inhibitor MG132. We
found that 4EGI-1–induced reduction of c-FLIP was abrogated by the
presence of MG132 in both H157 and H358 cell lines (Figure 6B),
suggesting that 4EGI-1–induced c-FLIP reduction is proteasome-
dependent. In addition, we determined whether 4EGI-1 increased
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c-FLIP ubiquitination. By immunoprecipitation/Western blot analysis,
we detected the highest levels of ubiquitinated FLIPL in cells treated with
4EGI-1 plus MG132 compared with cells exposed to 4EGI-1 alone or
MG132 alone (Figure 6C), indicating that 4EGI-1 increases c-FLIPubiq-
uitination. Collectively, we conclude that 4EGI-1 facilitates ubiquitin/
proteasome–mediated c-FLIP degradation, leading to down-regulation
of c-FLIP.
Discussion
In the present study, we have demonstrated that the eIF4E and
eIF4G interaction inhibitor 4EGI-1 effectively inhibited the growth
of human lung cancer cells and induces apoptosis. These findings are
consistent with previous work [39]. Moreover, we have shown that
4EGI-1 cooperates with TRAIL to augment induction of apoptosis
in a panel of human lung cancer cells. To the best of our knowledge,
Figure 4. 4EGI-1 disrupts eIF4E and eIF4G interaction (A) and inhibits cyclin D1 and HIF-1α expression (B); however, eIF4E siRNA decreases
cyclin D1 expression but does not induce DR5 expression, reduce c-FLIP levels (C) or enhance TRAIL-induced apoptosis (D and E). (A) H358
cells were treated with DMSO or 50 μM 4EGI-1 for 6 hours and then harvested for preparation of whole-cell protein lysates and subsequent
m7GTP pull-down assay. (B) The given cell lines were treated with different concentrations of 4EGI-1 as indicated for 24 hours (upper panel)
or 50 μM 4EGI-1 for the indicated times (lower panel) and then subjected to preparation of whole-cell protein lysates and subsequent
Western blot analysis. (C) H358 cells were transfected with 20 nM control (Ctrl) or eIF4E siRNA for the indicated times and then subjected
to preparation of whole-cell protein lysates and subsequent Western blot analysis. (D and E) A549 cells were transfected with 10 nM con-
trol (Ctrl) or eIF4E siRNA for 24 hours and then treated with 40 ng/ml TRAIL. After an additional 16 hours, the cells were harvested for either
Western blot analysis of the given proteins (D) or Annexin V assay for detection of apoptotic cells (E). CF indicates cleaved form.
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this is the first study to show the interaction between 4EGI-1 and
TRAIL/death receptor–induced apoptosis.
DR4, DR5, and c-FLIP are key components in the TRAIL-mediated
apoptotic pathway [23]. Modulation of their expression levels alters
cell sensitivity to TRAIL-induced apoptosis [26]. In this study, we
found that 4EGI-1 increased DR5 expression and reduced c-FLIP lev-
els in multiple lung cancer cell lines.WhenDR5 induction was blocked
by siRNA-mediated knockdown of DR5 expression or ectopic c-FLIP
was expressed, the cooperative induction of apoptosis by the 4EGI-1
and TRAIL combination was abrogated (Figure 3). Thus, we con-
clude that both DR5 induction and c-FLIP down-regulation are critical
events that mediate enhanced induction of apoptosis by the combina-
tion of 4EGI-1 and TRAIL. We noted that blockage of DR5 induction
or overexpression of ectopic c-FLIP also attenuated apoptosis induced
by 4EGI-1 alone (Figure 3), suggesting that DR5 induction and c-FLIP
reduction also contribute to 4EGI-1–induced apoptosis. Unexpectedly,
we also observed that DR4 expression was reduced by 4EGI-1 (Fig-
ure 3A). The mechanism underlying the down-regulation of DR4 by
4EGI-1 is unknown; however, this warrants our further investigation.
A previous study suggested that c-FLIP regulation in glioblastoma
multiforme cells involves an mTOR-dependent translational mecha-
nism [52]. Accordingly, rapamycin inhibited c-FLIP expression and
sensitized glioblastoma multiforme cells to TRAIL-induced apoptosis
[52]. In this study, 4EGI-1, as an eIF4E and eIF4G interaction inhibi-
tor, disrupted the interaction between eIF4E and eIF4G and inhibited
the expression of both cyclin D1 and HIF-1α, both of which are regu-
lated by cap-dependent translation mechanisms, in our cell systems
(i.e., lung cancer cells; Figure 4), indicating that 4EGI-1, as reported
[39], indeed inhibits eIF4F formation and cap-dependent protein trans-
lation. However, neither eIF4E siRNA (which inhibits eIF4F formation)
nor rapamycin (which inhibits mTOR-dependent protein translation)
increased DR5 expression, reduced c-FLIP levels or enhanced TRAIL-
induced apoptosis in our cell systems, although they did downregulate
the levels of cyclin D1 and HIF-1α (Figures 4 and W1). These data sug-
gest that 4EGI-1 is unlikely to modulate the levels of DR5 and c-FLIP
and augment TRAIL-induced apoptosis through inhibition of eIF4F-
mediated cap-dependent protein translation. Our data are in agreement
with another recent study showing that inhibition of mTOR with either
Figure 5. 4EGI-1 increases DR5 expression at the transcriptional level (A–C) through a CHOP-dependent mechanism (D and E). (A) The given
cell lines were treated with the indicated concentrations of 4EGI-1 for 12 hours and then subjected to preparation of total cellular RNA and
subsequent RT-PCR. (B and C) The given reporter constructs were cotransfected with pCH110 plasmid into H358 cells. After 24 hours,
the cells were treated with DMSO or 50 μM 4EGI-1 for 14 hours and then subjected to luciferase assay. Columns indicate means of tripli-
cate determinations; bars, ±SDs. (D) The indicated cell lines were treated with the given concentrations of 4EGI-1 for 24 hours (upper panel)
or 50 μM 4EGI-1 for the indicated times (lower panel). The cells were then harvested for preparation of whole-cell protein lysates and sub-
sequent Western blot analysis. (E) H358 cells were transfected with 60 nM control (Ctrl) or CHOP siRNA. After 48 hours, the cells were
treated with 50 μM 4EGI-1 for 14 hours and then subjected to preparation of whole-cell protein lysates and subsequent Western blot analy-
sis. CF indicates cleaved form.
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rapamycin or mTOR siRNA failed to enhance TRAIL-induced apopto-
sis in glioblastoma cells [53]. Thus, we suggest that 4EGI-1 modulates
the levels of DR5 and c-FLIP and enhances TRAIL-induced apoptosis
independent of inhibition of cap-dependent protein translation, for ex-
ample, through “off-target” mechanisms.
ER stress and CHOP have been demonstrated to be involved inDR5
regulation [44,50,54]. In this study, 4EGI-1 increased DR5 mRNA
and luciferase activity of the DR5 promoter (Figure 5), indicating that
4EGI-1 induces DR5 expression at the transcriptional level. More-
over, deletion and mutation analysis of the DR5 promoter revealed
that the presence of the CHOP binding site is required for transactiva-
tion of the DR5 promoter by 4EGI-1 (Figure 5, B and C ). In agree-
ment, we found that 4EGI-1 increased CHOP levels, which could be
detected even at 3 hours after 4EGI-1 treatment (Figure 5D), thus
preceding DR5 up-regulation that occurred 12 hours after 4EGI-1
treatment (Figure 3B). Importantly, blockade of CHOP induction by
silencing CHOP expression with CHOP siRNA abolished 4EGI-1’s
ability to induce DR5 expression (Figure 5E). Taken together, we con-
clude that 4EGI-1 induces a CHOP-dependent DR5 up-regulation.
CHOP is known to be a typical protein associated with ER stress–
induced apoptosis [55]. In addition to CHOP, we also detected in-
creases in ATF4 and p-eIF2a, two other ER stress–associated proteins,
in cells treated with 4EGI-1 (Figure 5D). Thus, it is possible that 4EGI-1
induces ER stress, leading to CHOP-dependent DR5 up-regulation. We
noted that CHOP blockage abolished not only DR5 induction but also
PARP cleavage by 4EGI-1 (Figure 5E), suggesting that CHOP induc-
tion is also important for 4EGI-1–induced apoptosis. This furthers our
notion that DR5 induction is important for 4EGI-1–induced apoptosis
as well.
c-FLIP proteins are known to be regulated by ubiquitin/proteasome–
mediated degradation [31–33]. In this study, we found that 4EGI-1
treatment reduced c-FLIP stability and the presence of the protea-
some inhibitor MG132 prevented c-FLIP from reduction by 4EGI-1.
Moreover, we detected increased levels of ubiquitinated c-FLIP in
cells cotreated with MG132 and 4EGI-1 using immunoprecipitation/
Western blot analysis (Figure 6). All together, we conclude that 4EGI-1
downregulates c-FLIP levels by facilitating ubiquitin/proteasome–
mediated degradation of c-FLIP.
In summary, the current study has revealed a novel biological func-
tion of 4EGI-1 that sensitizes human lung cancer cells to TRAIL-
induced apoptosis. Cooperative augmentation of apoptosis by the
4EGI-1 and TRAIL combination involves CHOP-dependent DR5
induction and ubiquitin/proteasome–mediated c-FLIP degradation in-
dependent of inhibition of cap-dependent protein translation.
Figure 6. 4EGI-1 decreases c-FLIP stability (A) and promotes ubiquitin/proteasome–mediated c-FLIP degradation (B and C). (A) H157 cells
were treated with DMSO or 50 μM 4EGI-1 for 5 hours. The cells were then washed with PBS three times and refed with fresh medium
containing 10 μg/ml CHX. At the indicated times, the cells were then harvested for preparation of whole-cell protein lysates and subsequent
Western blot analysis. Protein levels were quantitated with NIH Image J software (Bethesda, MD) and were normalized to actin. The re-
sults were plotted as the relative c-FLIP levels compared with those at the time 0 of CHX treatment (lower panel). (B) The indicated cell lines
were pretreatedwith 20 μMMG132 for 30minutes and then cotreatedwith 50 μM4EGI-1 for another 4 hours. The cells were then harvested
for preparation of whole-cell protein lysates and subsequentWestern blot analysis. NSB indicates nonspecific band. (C) H157-FLIPL-21 cells,
which stably express ectopic flag-FLIPL, were transfected with HA-ubiquitin plasmid using FuGENE 6 transfection reagent for 24 hours. The
cells were then pretreated with 20 μMMG132 for 30 minutes and then cotreated with 50 μM 4EGI-1 for 4 hours. Whole-cell protein lysates
were then prepared for immunoprecipitation using anti-Flag antibody followed by Western blot (WB) analysis using anti-HA antibody for
detection of ubiquitinated FLIPL (Ub-FLIPL) and anti-Flag antibody for detection of ectopic FLIPL.
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Figure W1. Rapamycin neither modulates the expression of DR5 and c-FLIP (A) nor sensitizes cancer cells to TRAIL-induced apoptosis
(B). (A) The indicated cell lines were treated with the different concentrations of rapamycin (Rap) as indicated. After 24 hours, the cells
were harvested for preparation of whole-cell protein lysates and subsequent Western blot analysis. (B) The indicated cell lines were
plated in 96-well plates and treated the next day with rapamycin (1-100 nM) alone, TRAIL alone (10 or 20 ng/ml) or the combination
of rapamycin and TRAIL. After 24 hours, cell numbers were estimated using the SRB assay. Cell survival was expressed as the percent
of control (DMSO-treated) cells. Columns indicate the means of four replicate determinations; bars, ±SDs.
